21 September 2018: Growing prevalence of chronic and infectious diseases is anticipated to stimulate demand for Isothermal Nucleic Acid Amplification Technology (INAAT). The INAAT technologies can expedite diagnostic procedures for various health disorders. Major technology variants of INAAT are nucleic acid sequence based amplification (NASBA), helicase-dependent amplification (HDA), transcription-mediated amplification (TMA), loop-mediated isothermal amplification (LAMP).
TMA to be the Leading Technology Segment
TMA is likely to be the dominating segment during the forecast period (from 2018 to 2025), being the first INAAT introduced for consumers. Increasing cases of chronic disorders, such as cancer and other infectious diseases, are predicted to impel demand for such medical technologies. Considering the rising demand, most manufacturing companies are focusing on R&D and technological advancements to offer advanced products.
For instance, Hologic recently announced its third Panther Fusion assay that got clearance from the FDA. This new assay can detect rhinovirus, adenovirus, and human metapneumovirus. Other two assays under Panther Fusion System are Panther Fusion Paraflu assay and Panther Fusion Flu A/B/RSV assay. All these assays deliver modular approach to syndromic respiratory tests.
Market Insights
The worldwide Isothermal Nucleic Acid Amplification Technology (INAAT) market is predicted to reach USD 4.3 billion by 2025, according to a report by Grand View Research, Inc. Growing geriatric population base is likely to drive the global market. Growing necessity for rapid, disease-specific, and user-friendly kits to stimulate diagnosis of various infections can exhilarate market growth. Rising adoption of molecular diagnostics owing to increase in disposable income can also augment the growth of this market.
Increasing cases of chronic infections, such as respiratory viral infections, diarrhea, and pneumonia, would also fuel market growth. Moreover, miniaturization of nucleic acid-based diagnostic procedures can impel demand for INAAT. Some of the prominent companies in the market are QIAGEN, Becton, Dickinson and Company, Quidel Corporation, and Thermo Fisher Scientific.
Read more @
No comments:
Post a Comment